New ambr 250 modular bioreactor vessel for cell and gene therapy applications

The ambr 250 modular bioreactor system can now even be used for cell and gene therapy applications.

Designed for gentle stirring and optimum growth of cell lines.

The new unbaffled vessel design with a large pitched blade impeller has a working volume of 100-250 mL and provides an environment for gentle agitation and mixing without sedimentation, allowing optimal growth of single cell suspensions, cell aggregates or adherent cells on microcarriers. In trials with leading regenerative medicine companies, the new mini bioreactor has shown better cell culture performance compared with less predictive spinner or T-flask models, enabling rapid process optimization and improved scalability to larger bioreactors.

To further support culture of these cell lines, ambr 250 modular systems also feature a new state-of-the-art motor (100 rpm-4,500 rpm), ideal for the lower stirrer speeds required by delicate therapeutic cell lines. The system is suitable for culturing cell lines including such as HEK293, CAR-T and other therapeutic cell lines, including a range of stem cells, enabling scalable media and supplement optimization, as well as process development of cell and gene therapies.

The bioreactor system is available with optional BioPAT MODDE software for DoE (Design of Experiments), to support QBD (Quality by Design) for scale-up to SSB’s BIOSTAT STR stirred bioreactors and scale-out to BIOSTAT RM TX rocking bags suitable for cGMP production of autologous and allogeneic cell and gene therapies.

"The ambr 250 systems are established as the biopharma industry standard small scale model for biologics process optimization, and we have been approached by numerous scientists developing cell and gene therapies to extend our technology for these applications,” explained Dr Barney Zoro, ambr Product Manager at SSB. “We have responded by designing a new vessel for the ambr 250 modular system to provide a single-use platform, with a clear scalable pathway to our bioreactors and bags for clinical production of regenerative medicines. Researchers utilizing this workflow, can benefit by reducing time-lines and minimizing manufacturing costs, thus allowing larger patient numbers to access these revolutionary therapies sooner,” Zoro added.